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ABSTRACT
Objective:Dignity therapy (DT) is a short-term psychotherapy developed for patients livingwith
a life-limiting illness. Our aim was to determine the influence of DTon symptoms of depression
and anxiety in people with a life-threatening disease with high level of distress, referred to an
inpatient palliative care unit.
Method:This was an open-label randomized controlled trial. Sixty terminally ill patients were
randomly assigned to one of two groups: intervention group (DTþ standard palliative care
[SPC]) or control group (SPC alone). The main outcomes were symptoms of depression and
anxiety, measured with the Hospital Anxiety and Depression Scale, assessed at baseline, day 4,
day 15, and day 30 of follow-up.
Results:Of the60participants, 29were randomized toDTand31 toSPC.Baseline characteristics
were similar between the two groups. DTwas associated with a significant decrease in depressive
symptoms at day 4 andday 15 (mean¼ 24.46, 95%CI,26.91–2.02,p¼ 0.001;mean¼ 23.96, 95%
CI,27.33 to20.61;p¼ 0.022, respectively), butnot at day30 (mean¼ 23.33, 95%CI,27.32–0.65,
p¼ 0.097).DTwasalsoassociatedwitha significantdecrease inanxietysymptomsat each follow-up
(mean¼ 23.96, 95% CI, 26.66 to 21.25, p¼ 0.005; mean¼ 26.19, 95% CI, 210.49 to 21.88, p¼
0.006; mean¼ 25.07, 95% CI, 210.22 to 20.09, p¼ 0.054, respectively).
Significance of results: DTappears to have a short-term beneficial effect on the depression and
anxiety symptoms that often accompany patients at the end of their lives. Future research with
larger samples compared with other treatments is needed to better understand the potential
benefits of this psychotherapy.
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INTRODUCTION
Terminally ill patients are often confronted with
psychological distress, which is one of the most debil-
itating conditions among dying patients (Boston
et al., 2011). The diagnosis of an incurable disease
can set patients into crisis, leaving them vulnerable
to depression and anxiety. Although psychological
distress is well documented in dying patients, it
tends to be under-recognized and frequently left un-
attended. This accentuates patient and family suffer-
ing, reducing quality of life and the ability to connect
with one another or come to terms with impending
losses (Block, 2000).
Depression is the most common psychological pro-
blem in the terminally ill and is known as a risk
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factor for suicide and requests for hastened death
(Chochinov et al., 1995). Terminally ill patients can
face anxiety as an isolated psychiatric disorder or
as a prominent component of acute or chronic phys-
ical symptoms such as pain or dyspnea.
Psychological suffering for terminally ill patients
is also often framed in terms of loss of dignity (Cho-
chinov, 2007). Although dignity is a core element of
palliative care, it was not well defined or operationa-
lized until the work of Chochinov and colleagues.
Their Model of Dignity provides an empirical frame-
work, offering insights regarding how patients face
terminal illness. This model provides the theoretical
basis for a brief, individualized intervention de-
signed to address psychosocial and existential dis-
tress among terminally ill patients, termed dignity
therapy (DT) (Chochinov et al., 2005).
Previous results conducted with patients with ad-
vanced cancer showed that, after performing DT,
91% of participants reported being satisfied; 76% re-
ported a heightened sense of dignity; 68% reported
an increased sense of purpose; 67% reported a heigh-
tened sense of meaning; and 47% reported an in-
creased will to live (Chochinov et al., 2005). A recent
trial of DT showed that although DT did not signifi-
cantly influence distress, those assigned to DTwhere
significantly more likely than other study groups to
find this approach helpful, and to experience im-
proved quality of life and an increased sense of dig-
nity. DT also changed how their family saw and
appreciated them, and was helpful to their family
(Chochinov et al., 2011). Because base rates of dis-
tresswere low in this study,DTdidnot showanyeffect
on patients´ depression and anxiety symptoms. As
such, the authors stressed the importance of future
research among more distressed patients to examine
its ability to mitigate outright distress. Prior studies
have shown that Portuguese cancer patients demon-
strate high levels of depression and anxiety symp-
toms as measured by the Hospital Anxiety and
Depression Scale (HADS) (Pais-Ribeiro et al., 2007).
The overall study objective was to provide data on
several psychosocial distress outcomes such as desire
for death, demoralization, loss of dignity, and de-
pression and anxiety symptoms. The present article
reports only the effect of DT on depression and
anxiety symptoms immediately post-intervention,
and at 15 and 30 day follow-up, in people with a
life-threatening disease being cared for within an in-
patient palliative medicine unit in Lisbon.
METHOD
This was an open-label randomized controlled trial
composed of two study arms: an intervention group,
consisting of DT in addition to standard palliative
care (SPC); and a control group, consisting of SPC
alone, with several evaluation assessments using the
HADSaccording to the investigationprotocol (Table1).
Participants
Patients were recruited from a 10 bed specialized pal-
liativemedicine unit of S. BentoMenni in Lisbon that
delivers differentiated palliative care to terminally ill
patients from the Portuguese National Palliative
Care Network. The recruitment took place over a 22
month period (from May 2010 to March 2012).
Inclusion criteria included: age  18 years old;
having a life-threatening diseasewith life expectancy
of  6 months or less; no evidence of dementia or de-
lirium, based on documentation within the medical
chart or by clinical consensus; Mini Mental State
score  20; being able to read and speak Portuguese;
provision of written informed consent; and being
available for four to five research encounters, over a
period of 1 month.
This study was approved by the Ethics Committee
of the Instituto das Irma˜s Hospitaleiras do Sagrado
Corac¸a˜o de Jesus - Casa de Sau´de da Idanha.
Randomization and Masking
The randomization process was computer generated,
using a fixed block of four, and was conducted by an
independent statistician. Allocation concealment
was made by using sequentially numbered envelopes
for consecutive trial participants. After the baseline
measures were collected by the secondary investi-
gator (FO), the envelope was opened in the presence
of the patient to reveal which study arm the patient
was assigned to. The principal investigator (MJ)
was not blind to patients´ study groups, but was blind
to the psychometric results throughout the entire
protocol. The secondary investigator was blind to
the content of DT sessions.
Interventions
SPC
SPC was provided by a multiprofessional palliative
medicine team, including three palliative care phys-
icians (including the principal investigator), nurses,
a psychologist, and psychosocial worker. Clinical
care consisted of daily (median ¼ 25 minutes; range
10–30) clinical interviews, physical examinations,
and symptom assessment and management.
Throughout their hospital stay, all patient and family
questions were responded to, and existential and psy-
chosocial support were offered. SPC was provided
throughout the patients’ hospital stay, including the
duration of time they were enrolled within this study.
As was the case with every other patient admitted to
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Table 1. Investigation protocol for each group.
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this unit, they were seen and managed by the entire
multiprofessional team.
DT
DTis abrief psychotherapeutic approachwith theaim
of bolstering the patient’s sense of meaning and pur-
pose, reinforcing a continued sense of worth within a
framework that is supportive, nurturing, and accessi-
ble for those near death. Patients enrolled in DT are
asked to audiorecord aspects of their lives that they
wouldmost want their loved ones to know about or re-
member. DT offers patients the opportunity to talk
about issues that matter the most to them, to share
moments that they feel were the most important and
meaningful; to speak about things that they would
like to be remembered by, or offeradvice to their family
and friends. These recorded sessions provide the basis
of an edited transcript – generativity document – that
is returned to patients for them to share with individ-
uals of their choosing.Creating this document ismeant
to make patients feel valued, and that something of
themselves will last beyond death.
Therapeutic sessions, running between 30 and 60
minutes, were offered at patients´ bedsides and audio-
recorded. Every tape-recorded session was erased
after the completion of the study protocol. This study
utilized theDTquestion framework (Chochinovet al.,
2002; 2005), as per previously published trials
(Table 2).AllDTwas conductedby theprincipal inves-
tigator (MJ) who attended an International DTwork-
shop held inWinnipeg, Canada; all procedures forDT
were conducted in accordance with the DT Manual
(Chochinov et al., 2002; 2005; Chochinov, 2011)
Patients meeting eligibility criteria and agreeing
to participate in the studywere asked to providewrit-
ten informed consent. Once patients completed the
baseline assessment (T1), those randomized to DT
were provided with the standard framework of ques-
tions, thus giving them time to reflect and shape
their eventual responses (Table 1). The taped DT ses-
sion was scheduled to take place within 2–3 days, or
as soon as the patient was available. Guided by the
DT framework, the therapists followed the patients’
cues, helping them to structure and organize their
thoughts. Once the taped session was complete,
over the course of the next 2–3 days, the patients’ re-
corded dialogue was transcribed verbatim and then
edited (as per theDT protocol/manual) and reshaped
into a written narrative. Once this editing process
was complete, another session was arranged as
soon as possible, for the therapist to read the docu-
ment to the patient, allowing for final editorial cor-
rections and revisions. The final version of the
generativity document was given to patients to be
passed along to the individuals of their choosing.
Outcomes
The outcome evaluatedwas the influence of DTon de-
pression and anxiety symptoms, measured with the
HADS, at baseline (T1), day 4 (T2), day 15 (T3,) and
day 30 (T4) of follow-up (Table 1). The HADS final
scores were known only at the end of the completion
of the study protocol of each patient.
Statistical Analysis
The datawere analyzed with the SPSSw 18.0 statisti-
cal package.
Based on previously published Portuguese studies
of the HADS in cancer populations (Pais-Ribeiro
et al., 2007), we considered a mean reduction of 1.5
points on the HADS depression subscale as clinically
significant. Assuming a type I error of 5%, a power of
80%, and a standard deviation of 2.5, each study arm
required at least 45 patients. Assuming a dropout
rate of 10%, we intended to include in the overall
study 50 patients in each group.
Our study protocol included two analyses: an in-
terim analysis after 60 participants were obtained
and another analysis at the end of the research (pre-
dicted year 2013). Therefore, this report includes
only the efficacy data on depression and anxiety
symptoms that were available by March 2012, for
the first 60 who completed the protocol.
We compared continuous variables and ordinal
rating scales using paired or independent t test as
Table 2. Dignity therapy question protocol
Tell me a little about your life history; particularly the
parts that you either remember most or think are the
most important? When did you feel most alive?
Are there particular things that you would want your
family to know about you, and are there particular
things you would want them to remember?
What are the most important roles you have played in your
life (family roles, vocational roles, community service
roles, etc)? Why were they so important to you, and what
do you think you accomplished within those roles?
What are your most important accomplishments, and what
do you feel most proud of?
Are there particular things that you feel still need to be
said to your loved ones, or things that you would want to
take the time to say once again?
What are your hopes and dreams for your loved ones?
What have you learned about life that you would want to
pass along to others? What advice or words of guidance
would you wish to pass along to your [son, daughter,
husband, wife, parents, other(s)]?
Are there words or perhaps even instructions you would
like to offer your family, in order to provide them with
comfort or solace?
In creating this permanent record, are there other things
that you would like included?
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appropriate. The criterion for statistical significance
was set at p , 0.05 in a two-tailed test. In order to
check the t test assumption of normality, we used
the Shapiro–Wilk test. Nonparametric tests
(Mann–Whitney test for comparisons between
groups and Wilcoxon test for comparisons within
groups) were also applied to validate the results ob-
tained with t tests. The statistical analysis was ap-
plied to all the patients who had at least one
complete evaluation at any given follow-up point
(T2, T3, T4 – per protocol analysis).
This study is registered with http://www.control-
led-trials.com/ISRCTN34354086.
RESULTS
Summarydemographicand illnessdataforbothgroups
are presented in Table 3. Baseline characteristics of
Table 3. Summary characteristics of the participants at baseline (n ¼ 60)
Control group (n ¼ 31) DT group (n ¼ 29)
Gender, n (%)
Male 13 (41.9) 14 (48.3)
Female 18 (58.1) 15 (51.7)
Age, years
mean (SD) 66.5 (12.4), range ¼ 41–90
≤65 13 (41.9) 17 (58.6)
.65 18 (58.1) 12 (41.4)
Race/Ethnicity, n (%)
Caucasian 29 (93.5) 28 (96.5)
African 1 (6.5) 1 (3.5)
Marital status, n (%)
Single 6 (19.4) 5 (17.2)
Married/ Common law 13 (41.9) 15 (51.7)
Divorced/separated 3 (9.7) 4 (13.8)
Widowed 9 (29.0) 5 (17.2)
Education, n (%)
Knows how to read and write (without instruction) 1 (3.2) 2 (6.9)
Primary school 14 (45.2) 10 (34.5)
High school 10 (32.2) 10 (34.5)
Licensure 6 (19.4) 7 (24.1)
Religion, n (%)
Catholic 26 (83.9) 26 (89.7)
Other 5 (16.1) 3 (10.3)
Diagnosis, n (%)
Cancera 29 (93.5) 28 (96.5)
Non-cancerb 2 (6.5) 1 (3.5)
Time since diagnosisc, n (%)
,1 year 2 (6.5) 4 (13.8)
1–2 years 11 (35.5) 5 (17.2)
≥2 years 18 (58.0) 20 (69.0)
Psychiatric drugs, n (%)
Antidepressants 17 (54.8) 18 (62.1)
Anxiolytics 16 (51.6) 15 (51.7)
Neuroleptics 0 (0) 1 (3.5)
Anticonvulsivants 10 (32.3) 11 (37.9)
Palliative Performance Scaled
54.8 (16.9), range ¼ 30–90
mean (SD) 55.5 (18.0) 54.1 (15.9)
Mini Mental State
24.1 (2.0), range ¼ 20–28
Mean (SD) 23.8 (1.9) 24.4 (2.1)
aLung, n¼10; ovarian, n ¼ 5; breast, n ¼ 4; glioblastoma, n ¼ 4; uterus, n ¼ 4; tongue, n ¼ 3; bladder, n ¼ 2; cecum, n ¼ 2;
endometrium, n¼ 2; esophagus, n¼ 2; larynx, n ¼ 2; stomach, n¼ 2; prostate, n¼ 2; unknown primary cancer, n¼ 2; chronic
myeloid leukemia, n¼ 1; dorsal neurinoma, n ¼ 1; glioma, n ¼ 1;melanoma, n¼ 1; neoplasm of the nose, n¼ 1; pancreas, n¼
1; small bowel neuroendocrine tumor, n ¼ 1;vascular arterial cancer, n¼ 1.
bLateral amyotrophic sclerosis, n ¼ 2; trigeminal neuralgia, n ¼ 1.
c Based on medical records or patients information.
dPalliative Performance Scale: 100% - healthy; 0% - death.
DT, dignity therapy.
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thepatientswere similar between the twogroups.Over
a 22month period, 127 patients were admitted into the
palliative care unit ward; 70 patients were assessed for
eligibility, 60 of whom were randomized (29 to DT and
31 to SPC) (Fig. 1). After randomization, one patient
died before receivingDTand another one presented se-
vere clinical deterioration; six patients were lost to fol-
low-up at T2 (DT: n ¼ 2; SPC: n ¼ 4); 15 patients were
lost to follow-upatT3 (DT:n¼ 7;SPC:n ¼ 6)andanad-
ditional nine were lost to follow-up at T4 (DT: n ¼ 3;
SPC: n ¼ 6) (Fig. 1).
The mean survival time was 26.8 days (DT ¼ 25.8,
SPC ¼ 27.8; p ¼ 0.385).
Depression
Both groups had a mean score (SD) on the HADS de-
pression subscale. 11 at baseline (SPC:13.37 [4.06];
DT:12.90 [4.80]; p ¼ 0.708).
Patients assigned to DT demonstrated a signifi-
cant decrease on depression ratings at day 4 and at
day 15 (mean ¼ 22.76, 95% CI, 24.86 to 20.66,
p ¼ 0.012; mean ¼ 21.44, 95% CI, 24.53–1.64, p ¼
0.034, respectively), which plateaued by day 30 as-
sessments (mean ¼ 0.06, 95% CI, 23.65–3.78, p ¼
0.970) (Table 4).
Compared with the SPC group, those receiving DT
demonstrated a significant reduction in depression
ratings between baseline and day 4 assessment
(mean ¼ 24.46, 95% CI, 26.91 to 22.02, p ¼
0.001); these differences across groups were main-
tained at day 15 (mean ¼ 23.96, 95% CI, 27.33 to
20.61, p ¼ 0.022) but not at day 30 (mean ¼
23.33, 95% CI, 27.32–0.65, p ¼ 0.097) (Table 4).
Within the SPC group, there was a significant in-
crease in depression ratings between baseline and
all subsequent follow-up assessments (mean ¼ 1.70,
95% CI, 0.35–3.01, p ¼ 0.016; mean¼ 2.52, 95% CI,
1.02–4.03, p ¼ 0.002; mean ¼ 3.40, 95% CI, 1.66–
5.14, p ¼ 0.001, respectively) (Table 4, Fig. 2).
The t test normality assumption was rejected for
the time measures of HADS depression subscale at
Fig. 1. Consort diagram.
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post-intervention and day 15 in the control group. Re-
sults obtained by the nonparametric tests confirmed
the parametric test findings, with the exception of
day 30 (Table 4).
Anxiety
Both groups had a mean score (SD) on the HADS
anxiety subscale ,11 at baseline (SPC:8.40 [4.55];
DT:8.83 [4.97]; p ¼ 0.731).
Compared with the SPC group, those receiving
DT demonstrated significantly lower anxiety ratings
at all assessment periods (post-intervention:
mean ¼ 23.96, 95% CI, 26.66 to 21.25, p ¼ 0.005;
day 15: mean ¼ 26.19, 95% CI, 210.49 to 21.88,
p ¼ 0.006; day 30: mean ¼ 25.07, 95% CI, 210.22–
0.09, p ¼ 0.054) (Table 5).
Within the DT group, there was a significant re-
duction on anxiety ratings between baseline and
day 4 assessment (mean ¼ 23.44, 95% CI, 25.42 to
21.46, p ¼ 0.001), whichwasmaintained throughout
the follow-up period (day 15: mean ¼ 24.33, 95% CI,
27.68 to 20.99, p ¼ 0.014; day 30: mean ¼24.07,
95% CI, 27.79 to 20.34, p ¼ 0.034) (Table 5, Fig. 3).
In the SPC group, there were no significant chan-
ges on the HADS anxiety subscale between baseline
and day 4, or throughout the subsequent follow-ups
(mean ¼ 0.52, 95% CI, 21.42–2.46, p ¼ 0.588;
mean¼ 1.86, 95% CI, 21.08–4.79, p ¼ 0.202;
mean ¼ 1.00, 95% CI, 22.91–4.91, p ¼ 0.591)
(Table 5).
Table 4. Primary efficacy outcome variable: HADS depression subscale score within and between study groups
Control group DT group
Difference from baseline
n 27 25
mean (95% CI) 1.70 (0.35, 3.01) 22.76 (24.86,-0.66)
T2 p value 0.016a; 0.012b 0.012a; 0.010b
Difference between groups
mean (95% CI) 24.46 (26.91, 22.02)
p value 0.001c; ,0.0001d
Difference from baseline
n 21 18
mean (95% CI) 2.52 (1.02, 4.03) 21.44 (24.53, 1.64)
T3 p value 0.002a; 0.003b 0.034a; 0.367b
Difference between groups
mean (95% CI) 23.96 (27.33, 20.61)
p value 0.022c; 0.062d
Difference from baseline
n 15 15
mean (95% CI) 3.40 (1.66, 5.14) 0.06 (2 3.65, 3.78)
T4 p value 0.001a; 0.002b 0.970a; 0.801b
Difference between groups
mean (95% CI) 23.33 (27.32, 0.65);
p value 0.097c; 0.173d
Evaluation time points: T2 ¼ post-intervention; T3 ¼ day 15; T4 ¼ day 30.
a Paired t test.
b Wilcoxon test.
c independent t test.
d Mann-Whitney test.
CI, confidence interval; DT, dignity therapy; HADS, Hospital Anxiety & Depression Scale.
Fig. 2. Changes from baseline on HADS depression subscale
mean score. DT ¼ dignity therapy; SPC ¼ standard palliative
care; HADS ¼Hospital Anxiety & Depression Scale. T2 ¼ day 4;
T3 ¼ day 15; T4 ¼ day 30. *Independent t test, p, 0.05. †Indepen-
dent t test, p¼0.097.
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Normality assumption was not rejected for any of
the timemeasures using theHADS anxiety subscale.
Nonetheless, nonparametric tests were also applied,
confirming the t test findings (Table 5).
DISCUSSION
As previously demonstrated in the Portuguese can-
cer population (Pais-Ribeiro et al., 2007), our data
evidence a high level of depression and anxiety symp-
toms at baseline. DT research has been shown to en-
hance end-of-life experience, but has not as yet been
shown to ameliorate depression and anxiety symp-
toms in more severely distressed patients such as
our patient sample. In fact, low base rates of distress
were posited as an explanation for the inability to de-
monstrate DT’s influence on depression or anxiety in
prior clinical trials (Chochinov, 2011). On that front,
this Portuguese cohort was clearlymore distressed at
baseline than that in the Chochinov et al. study
(mean HADS-depression ¼ 12.9 versus 5.86; mean
HADS-anxiety ¼ 8.83 versus 5.22, respectively).
Patients who received DTwere significantly more
likely than SPC patients to experience reductions
in depression ratings immediately post-treatment,
with improvement being sustained throughout sub-
sequent follow-up, with the exception of depression
on day 30. The lack of efficacy of DT on reducing
HADS-depression scores at day 30 could suggest
that one single DT session might not be enough
to ameliorate and maintain the reductions in
Table 5. Primary efficacy outcome variable: HADS anxiety subscale score within and between study groups
Control group DT group
Difference from baseline
n 27 25
mean (95% CI) 0.52 (2 1.42, 2.46) 23.44 (25.42, 21.46)
T2 p value 0.588a; 0.146b 0.001a; 0.002b
Difference between groups
mean (95% CI) 23.96 (26.66, 21.25)
p value 0.005c; 0.001d
Difference from baseline
n 21 18
mean (95% CI) 1.86 (2 1.08, 4.79) 24.33 (27.68, 20.99)
T3 p value 0.202a; 0.191b 0.014a; 0.015b
Difference between groups
mean (95% CI) 26.19 (210.49, 21.88)
p value 0.006c; 0.007d
Difference from baseline
n 15 15
mean (95% CI) 1.00 (2 2.91, 4.91) 24.07 (27.79, 20.34)
T4 p value 0.591a; 0.555b 0.034a; 0.025b
Difference between groups
mean (95% CI) 25.07 (210.22, 0.09)
p value 0.054c; 0.042d
Evaluation time points: T2 ¼ post-intervention; T3 ¼ day 15; T4 ¼ day 30.
a Paired t test.
b Wilcoxon test.
c Independent t test.
d Mann-Whitney test.
CI, confidence interval; DT, dignity therapy; HADS, Hospital Anxiety & Depression Scale.
Fig. 3. Changes from baseline on HADS anxiety subscale mean
score. DT¼ dignity therapy. SPC ¼ standard palliative care.
HADS ¼Hospital Anxiety & Depression Scale. T2 ¼ day 4; T3 ¼
day 15; T4 ¼ day 30. *Independent t test, p , 0.05. †Independent
t test, p ¼ 0.054.
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depressive symptoms of patients facing death. These
findings beg the question of whether a second follow-
up session might reinforce the initial improvements
yielded by DT. Future research exploring this thera-
peutic approach would be of great value.
Even though our patient population had a high
level of psychosocial distress, DTwas offered to every
eligible participant without considering the presence
or intensity of psychological distress at baseline. Our
results show that patients with high levels of distress
can perform DTwithout distortion or misrepresenta-
tion of their life narratives.
Similar findings were demonstrated in terms of
DT’s ability to mitigate anxiety. These findings are
notable, given that Chochinov and colleagues’ re-
cent trial (Chochinov et al., 2011) was unable to de-
monstrate a significant effect of DT on anxiety. Low
base rates of distress were posited as an explanation
for the inability to demonstrate DT’s influence on
this outcome. By allowing patients to remember,
speak about their past, and share important reflec-
tions, DT brings these special moments to the pre-
sent, reaffirming a sense of meaning and purpose.
The therapeutic process, along with the opportunity
to create a personal generativity document, offers
patients the opportunity to actively engage in a vital
role, diminishing their sense of helplessness and
despair.
Perhaps patients who engage in DT are able to
move beyond their sadness, to an activity imbued
with meaning and purpose. It may also be that as
patients focused on their responses, experiencing a
degree of distraction that manifested itself as a re-
duction of anxiety; although it is interesting to note
that this effect was sustained well beyond the time
of therapeutic engagement.
There are several limitations to this study worth
noting. As in other published DT studies (Chochinov
et al., 2002; 2005; 2011) our research took place pri-
marily among older patients. As such, the influence
of DT within younger cohorts has yet to be estab-
lished. We also acknowledge that the study sample
size was small, which speaks for the reality of doing
longitudinal studies in very sick palliative care popu-
lations. In spite of this limitation, there are substan-
tial between-group statistical differences, indicating
clinically significant improvement. Finally, the ma-
jority of the study participants had end-stage malig-
nancies. Future research may explore the utility of
DT for other terminal conditions, such as end-stage
organ failure diseases. Within this trial, DTwas per-
formed exclusively by the principal investigator
(MJ), who strictly followed the DT protocol (Chochi-
nov, 2011) and received training provided by the orig-
inators of this therapeutic approach. The DT
therapist was not blinded to the study arm assign-
ment, however, patients in both groups received
equal quality palliative care (SPC) and all evalu-
ations, treatment plans, and direct interventions
were conducted, as per unit protocol, by the entire
multidisciplinary team. Despite these limitations,
this study provides compelling support for the effi-
cacy of DT in addressing symptoms of anxiety and de-
pression among patients.
Dignity therapy appears to have short-term
benefits on the psychological distress encountered
by patients near the end of life. This has important
future clinical and research implications; DT should
now be evaluated relative to other treatment options
such as psychotherapy or the use of psychopharma-
ceuticals.
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